Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 9834084 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Calvo J, et al. (1998) Human CD5 signaling and constitutive phosphorylation of C-terminal serine residues by casein kinase II. J Immunol 161, 6022-9 9834084
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S482-p - CD5 (human) ▲
Orthologous residues
CD5 (human): S482‑p, CD5 (mouse): S481‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte) [CD5 (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2-A1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heparin decrease
phorbol ester increase
heparin phorbol ester inhibit treatment-induced increase

S483-p - CD5 (human) ▲
Orthologous residues
CD5 (human): S483‑p, CD5 (mouse): S482‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte) [CD5 (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2-A1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heparin decrease
phorbol ester increase
heparin phorbol ester inhibit treatment-induced increase

S485-p - CD5 (human) ▲
Orthologous residues
CD5 (human): S485‑p, CD5 (mouse): S484‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, immunoprecipitation, mutation of modification site
 Disease tissue studied:  Fanconi's anaemia
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte) [CD5 (human)]
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE CK2-A1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2-A1 (human) pharmacological inhibitor of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heparin decrease
phorbol ester increase
heparin phorbol ester inhibit treatment-induced increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.